Biotech Values

[hptaxis]

Amgen's PCSK9 Inhibitor Reduced LDL Cholesterol up to 81 Percent in Phase 1b Study
Robust AMG 145 Phase 2 Program Expected to Deliver Results in 2012
http://wwwext.amgen.com/media/media_pr_detail.jsp?year=2012&releaseID=1676152

THOUSAND OAKS, Calif., March 25, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced today positive results from a Phase 1b clinical study of AMG 145, an investigational PCSK9 inhibitor, in patients with high cholesterol who were taking statins. The study demonstrated that multiple doses of AMG 145 significantly reduced serum low density lipoprotein cholesterol (LDL-C), also known as "bad" cholesterol, by up to 81 percent versus placebo (maximum reduction) in subjects on low to moderate doses of statins (p<0.001). The cholesterol lowering effects of AMG 145 were similar among patients on high doses of statins (80 mg atorvastatin and 40 mg rosuvastatin) and patients on low to moderate doses of statins. No deaths or serious adverse events (AEs) were reported in the study. Full results of the study were presented for the first time today in an oral session at the American College of Cardiology Scientific Session in Chicago. (Abstract # 923-4)